IRs and HRs of TB by biological exposure with etanercept as reference group according to three exposure definitions (ever-exposed, most recent exposure and current exposure/on drug) 2002–2011
| Ever-exposed | Most recent exposure | Current exposure/on drug | |||||||
|---|---|---|---|---|---|---|---|---|---|
| TB Cases/ py | Crude IR (95% CI) per 100 000 py | HR* (95% CI) | TB Cases/py | Crude IR (95% CI) per 100 000 py | HR* (95% CI) | TB Cases/py | Crude IR (95% CI) per 100 000 py | HR* (95% CI) | |
| Etanercept | 5/25 622 | 19.5 (6.3 to 45.5) | 1.0 (ref) | 3/19 044 | 15.7 (3.2 to 46.0) | 1.0 (ref) | 2/16 778 | 11.9 (1.4 to 43.1) | 1.0 (ref) |
| Infliximab | 10/19 454 | 51.4 (24.6 to 94.5) | 2.0 (0.6 to 5.9) | 8/11 902 | 67.2 (29.0 to 132.4) | 2.7 (0.7 to 10.9) | 5/9889 | 50.6 (16.4 to 118.0) | 2.4 (0.4 to 13.7) |
| Adalimumab | 8/16 865 | 47.4 (20.5 to 93.5) | 2.3 (0.8 to 7.2) | 6/11 447 | 52.4 (19.2 to 114.1) | 3.1 (0.8 to 12.5) | 6/9635 | 62.3 (22.9 to 135.5) | 4.7 (1.0 to 23.5) |
| Rituximab | 1/4172 | 24.0 (0.6 to 133.5) | 0.7 (0.1 to 7.5) | 1/3446 | 29.0 (0.7 to 161.7) | 0.6 (0.1 to 7.0) | 1/3204 | 31.2 (0.8 to 173.9) | 1.4 (0.1 to 21.0) |
| Abatacept | 0/1120 | 0 (0 to 267.5) | – | 0/818 | 0 (0 to 366.2) | – | 0/789 | 0 (0 to 379.7) | – |
| Anakinra | 0/1100 | 0 (0 to 272.3) | – | 0/541 | 0 (0 to 553.7) | – | 0/376 | 0 (0 to 796.7)) | – |
| Tocilizumab | 0/725 | 0 (0 to 413.2) | – | 0/600 | 0 (0 to 499.3) | – | 0/581 | 0 (0 to 515.6) | – |
| Golimumab | 0/279 | 0 (0 to 1073.7) | – | 0/237 | 0 (0 to 1264.0) | – | 0/243 | 0 (0 to 1232.8) | – |
| Certolizumab Pegol | 0/246 | 0 (0 to 1217.8) | – | 0/208 | 0 (0 to 1440.3) | – | 0/204 | 0 (0 to 1468.5) | – |
Ever-exposed: follow-up continued from start of the first ever biologic until end of study regardless of starting a second biological and/or discontinuation. Most recent exposure: follow-up ended at start of a subsequent biological treatment ignoring any discontinuation date of the previous biologic. Current exposure/on drug: follow-up ended at discontinuation of first ever biologic plus a 90-day washout.
*Adjusted HR (95% CI) estimated from Cox proportional hazard models comparing each biological to etanercept adjusted for age, sex, country of birth (Nordic vs non-Nordic), education (>9 years vs ≤9 years) and stratified by calendar period.
py; person-years, TB; tuberculosis, IR; incidence rate.